June 11, 2025 10:32 AM EDT

Lilly pledges more than $650M to muscle health biotech; Cogent gets $50M

ENDPOINTS

Plus, news about Cellectar Biosciences, Bausch + Lomb, Elkedonia, Pharmazz and Roche:

Eli Lilly turns to muscle health biotech: The drugmaker and

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Kennedy's vaccine doubts hinge on 'inert' placebos, but experts say he misunderstands the science

Exclusive: Kennedy picks for vaccine advisory board were paid experts against Merck in civil cases

CureVac CEO on BioNTech deal: Come together 'rather than fighting each other in court'

Insmed aims to raise $750M in one of the largest stock offerings this year

In surprise, FDA approves UroGen's chemo-turned-gel drug after negative adcomm vote

sponsored

McKesson leads the charge in revolutionizing precision oncology in community practices